is retatrutide safe for women Weight Loss Truth Retatrutide: A Promising Solution for

Clinical trials have reported favorable outcomes with GLP-1 medicines in individuals with metabolic dysfunction-associated steatohepatitis

Fatigue is not the most common side effect, but some people experience lower energy as their body adjusts to reduced calorie intake, blood sugar shifts and metabolic changes

In these clinical trials, researchers study things like side effects and how well the drug works

Telogen effluvium typically resolves within 36 months once the triggering factor stabilises

Earlier evidence for retatrutide comes from a Phase 2 trial in NEJM in 2023, which reported 24.2% weight loss at 12 mg over 48 weeks

What is clear is that patients should continue taking their GLP-1 receptor agonists in the perioperative period